NCT07469956 2026-03-13
Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer
Sun Yat-sen University
Phase 2 Not yet recruiting
Clinical Trials
25 trialsNCT07436741 2026-02-27
Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Not yet recruiting
NCT06361888 2025-12-30
A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
Hutchmed
Phase 2/3 Recruiting
NCT05472948 2025-12-17
Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma
Sun Yat-sen University
Phase 2 Recruiting
NCT05481476 2025-09-04
Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer
Sun Yat-sen University
Phase 2 Active not recruiting
NCT05481463 2025-05-28
Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer
Sun Yat-sen University
Phase 2 Completed
NCT04579757 2025-05-08
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Hutchmed
Phase 1/2 Terminated
NCT05218889 2024-12-31
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT06239532 2024-11-21
HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma
Qilu Hospital of Shandong University
Phase 2 Active not recruiting
NCT06531291 2024-07-31
Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation
RenJi Hospital
Phase 2 Not yet recruiting
NCT05832892 2024-06-14
Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer
Shanghai Zhongshan Hospital
Phase 1/2 Unknown
NCT06447636 2024-06-07
Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma
Fudan University
Phase 2 Not yet recruiting
NCT06375642 2024-04-19
A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT06255262 2024-02-13
Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer
China Medical University, China
Phase 1/2 Unknown
NCT06134193 2023-11-18
Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT05988372 2023-11-01
Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT04653480 2023-07-17
Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC
Zhejiang University
Phase 2 Unknown
NCT05627427 2022-11-25
Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05171439 2022-04-14
Surufatinib in Advanced Hepatocellular Carcinoma Based on Single-cell Sequencing of Tumor Samples
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Unknown
NCT05282433 2022-03-16
Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma
Zhongnan Hospital
Phase 2 Unknown
NCT05056116 2021-12-27
A Safety and Efficacy Study of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer
The Affiliated Hospital of Xuzhou Medical University
Phase NA Unknown
NCT04764006 2021-11-04
Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study
Fujian Cancer Hospital
Phase 2 Unknown
NCT04929652 2021-06-18
Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal Cancer
Jiangsu Cancer Institute & Hospital
Phase 1/2 Unknown
NCT03873532 2020-02-13
A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients
Hutchmed
Phase 2/3 Unknown
NCT02966821 2019-02-27
Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma
Hutchmed
Phase 2 Completed